产品说明书
Subasumstat
 |
同义名 : | TAK-981 |
| CAS号 : | 1858276-04-6 | |
| 货号 : | A1150252 | |
| 分子式 : | C25H28ClN5O5S2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 578.103 | |
| MDL号 : | MFCD32062692 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 16 mg/mL(27.68 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | TAK-981 is a new small molecule inhibitor of sumoylation. Through intravenous administration, TAK-981 targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, preventing SUMO conjugation to lysine residues on target proteins and abrogating many sumoylated protein-mediated cellular processes that play key roles in tumor cells, including proliferation, DNA repair, metastasis and survival. Through preventing sumoylation, TAK-981 is able to increase the production of type 1 IFN and thereby increases type 1 IFN-mediated signaling, activates innate effector cells and enhances the antitumor innate immune responses. This may further increase tumor cell killing. These suggest TAK-981 may have potential immune-activating and antineoplastic activities. | ||
| 作用机制 | TAK-981 could covalently bind to SUMO protein and form an adduct with SUMO protein, which prevents the transfer of SUMO from the SUMO-activating enzyme (SAE) to SUMO-conjugating enzyme UBC9.[1] | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.73mL 0.35mL 0.17mL |
8.65mL 1.73mL 0.86mL |
17.30mL 3.46mL 1.73mL |
| 参考文献 |
|---|